PRDX4 and ovarian cancer: Sehrawat et al. [77] observed that PRDX4 expression was up-regulated in drug resistance to advanced ovarian cancer patients receiving first-line chemotherapy of paclitaxel and carboplatin, suggesting that PRDX4 may act as a candidate biomarker to predict chemotherapy response in ovarian cancer.